secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001453687-24-000088
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian stockholders elect directors, approve incentive plan, ratify auditor at annual meeting
--------------------------------------------------------------------------------

- Carrie S. Cox (11.8M for) and Murat Kalayoglu (12.1M for) elected to Class II board until 2027.
- Stockholders approved amended & restated 2016 Incentive Award Plan (11.3M for, 857K against).
- Non-binding advisory vote on executive compensation passed (11.7M for, 444K against).
- Ernst & Young ratified as independent auditor for 2024 (13.5M for, 212K against).
- Annual meeting turnout: 13.8M shares voted, ~77.3% of outstanding common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000088/0001453687-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000088/rnac-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer